AOD-9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-06-15. Anything still debated is marked as such rather than presented as settled.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
The burning wells needed to be extinguished as, without active efforts, Kuwait would lose billions of dollars in oil revenues. It was predicted by experts that the fires would burn for between two and five years before losing pressure and going out on their own. The companies responsible for extinguishing the fires initially were Bechtel, Red Adair Company (now sold to Global Industries of Louisiana), Boots and Coots, and Wild Well Control. Safety Boss was the fourth company to arrive but ended up extinguishing and capping the most wells of any other company: 180 of the 600. Other companies including Cudd Well/Pressure Control, Neal Adams Firefighters, and Kuwait Wild Well Killers were also contracted. According to Larry H. Flak, a petroleum engineer for Boots and Coots International Well Control, 90% of all the 1991 fires in Kuwait were put out with nothing but sea water, sprayed from powerful hoses at the base of the fire. The extinguishing water was supplied to the arid desert region by re-purposing the oil pipelines that prior to the arson attack had pumped oil from the wells to the Persian Gulf. The pipeline had been mildly damaged but, once repaired, its flow was reversed to pump Persian gulf seawater to the burning oil wells. The extinguishing rate was approximately 1 every 7–10 days at the start of efforts but then with experience gained and the removal of the mine fields that surrounded the burning wells, the rate increased to 2 or more per day.
=== Female pheromones === cis-7-dodecenyl acetate cis-5-dodecenyl acetate 11-dodecenyl acetate cis-7-tetradecenyl acetate cis-9-tetradecenyl acetate dodecyl acetate Cabbage loopers are unique in that both females and males release pheromones in order to seek a mate. Generally, females release pheromones from the tips of their abdomens, and males seek females upon detection. Females around host plants are more attractive to males, possibly because females release more pheromones in the presence of host plant odor. Although it is not clear why host plant odors incite female pheromone production, this response may help reduce time wasted spent searching for a mate and therefore increase the chance of mating. Female cabbage loopers usually attract the male, as females have more to lose by spending energy and time on searching for a mate.
Multiple Republican-led administrations removed voters from their states' voter rolls in the lead up to the election, which critics argued violates the National Voter Registration Act. In July 2024, 160,000 inactive or infrequent voters were removed from Ohio's voter rolls. The Ohio chapters of Common Cause and the League of Women Voters threatened lawsuits against the state over the purge. In August 2024, Governor Glenn Youngkin of Virginia signed an executive order removing 6,303 voters suspected of being non-citizens from Virginia's voter rolls. In October 2024, the U.S. Department of Justice sued the Virginia Board of Elections and Virginia commissioner of elections over the voter purge, alleging that it violated the National Voter Registration Act. The suit also found a number of alleged non-citizens purged were actually citizens. District judge Patricia Tolliver Giles ruled that the removal was illegal, ordering the state to stop purging voter rolls and to restore the voter registration of more than 1,600 voters who had been removed. The 4th Circuit Court of Appeals then upheld the order. The administration filed an emergency appeal to the U.S. Supreme Court, which sided with Virginia in a 6–3 decision along ideological lines, allowing the state to continue purging voter rolls. In August 2024, Alabama Secretary of State Wes Allen announced a process for purging 3,251 registered Alabama voters and referred them to the state attorney general's office for criminal prosecution.
=== EC 1.6.4 With a disulfide as acceptor (deleted sub-class) === EC 1.6.4.1: now EC 1.8.1.6 cystine reductase EC 1.6.4.2: now EC 1.8.1.7 glutathione-disulfide reductase EC 1.6.4.3: now EC 1.8.1.4 dihydrolipoyl dehydrogenase EC 1.6.4.4: now EC 1.8.1.8 protein-disulfide reductase EC 1.6.4.5: now EC 1.8.1.9 thioredoxin-disulfide reductase EC 1.6.4.6: now EC 1.8.1.10 CoA-glutathione reductase EC 1.6.4.7: now EC 1.8.1.11 asparagusate reductase EC 1.6.4.8: now EC 1.8.1.12 trypanothione-disulfide reductase EC 1.6.4.9: now EC 1.8.1.13 bis-γ-glutamylcystine reductase EC 1.6.4.10: now EC 1.8.1.14 CoA-disulfide reductase
Sources: en.wikipedia.org
== History == Sarepta started in Corvallis, Oregon on January 1, 1980 and was originally named Antivirals Inc. After occupying several research laboratory spaces in Corvallis, the company opened a production laboratory in Corvallis in February 2002 and was renamed AVI BioPharma Inc. The company made headlines in 2003 when it announced work on treatments for severe acute respiratory syndrome (SARS) and the West Nile virus. In July 2009, the company announced they would move their headquarters from Portland, Oregon, north to Bothell, Washington, near Seattle. At that time, the company led by president and CEO Leslie Hudson had 83 employees and quarterly revenues of $3.2 million. AVI had yet to turn a profit and had not yet developed any commercial products as of July 2009. The company lost $19.7 million in the second quarter of 2009, and then won an $11.5 million contract with the U.S. Department of Defense's Defense Threat Reduction Agency in October 2009. By this time, the company had completed its headquarters move to Bothell. In 2012, the company moved a second time, to Cambridge, Massachusetts. At the time, CEO Chris Garabedian indicated the move was motivated by the need to recruit expertise in rare diseases. The Corvallis laboratory facility was closed in 2016. In June 2017, Sarepta Therapeutics appointed former Allergan executive Doug Ingram as its new CEO to replace Edward Kaye who had announced plans to step down earlier that year.
inborn error of metabolism Any genetically determined biochemical variation affecting one or more metabolic functions in a way that causes a congenital disease or disorder in humans. Most such errors are due to mutations in single genes encoding enzymes that facilitate important metabolic reactions such as the conversion of specific substrates into unique products, which may affect numerous downstream steps in one or more metabolic pathways and thereby contribute to a diverse variety of symptoms; often they cause the accumulation of toxic intermediates or impair the body's ability to synthesize essential compounds.
=== Modeling of side-chain conformations === Accurate packing of the amino acid side chains represents a separate problem in protein structure prediction. Methods that specifically address the problem of predicting side-chain geometry include dead-end elimination and the self-consistent mean field methods. The side chain conformations with low energy are usually determined on the rigid polypeptide backbone and using a set of discrete side chain conformations known as "rotamers". The methods attempt to identify the set of rotamers that minimize the model's overall energy. These methods use rotamer libraries, which are collections of favorable conformations for each residue type in proteins. Rotamer libraries may contain information about the conformation, its frequency, and the standard deviations about mean dihedral angles, which can be used in sampling. Rotamer libraries are derived from structural bioinformatics or other statistical analysis of side-chain conformations in known experimental structures of proteins, such as by clustering the observed conformations for tetrahedral carbons near the staggered (60°, 180°, −60°) values. Rotamer libraries can be backbone-independent, secondary-structure-dependent, or backbone-dependent. Backbone-independent rotamer libraries make no reference to backbone conformation, and are calculated from all available side chains of a certain type (for instance, the first example of a rotamer library, done by Ponder and Richards at Yale in 1987).
Sources: en.wikipedia.org
== Uses == BPF is used in the manufacture of plastics and epoxy resins. It is used in the production of tank and pipe linings, industrial flooring, road and bridge deck toppings, structural adhesives, grouts, coatings and electrical varnishes. BPF is also utilized in liners, lacquers, adhesives, plastics, and the coating of drinks and food cans. BPF is found in dental materials, such as restorative materials, liners, adhesives, oral prosthetic devices and tissue substitutes.
The resultant PCR amplicons encoding fl-DHX8 (M1 to R1220) or DHX8Δ547 (A548 to R1220) are inserted into the "pFBDM" vector downstream of the polyhedrin promoter. Both, vector and insert, are digested with BamHI and NotI restriction enzymes.
anomer Either of a pair of cyclic hemiacetal or hemiketal saccharides that are epimers of each other, differing at only one carbon stereocenter, specifically the carbon that bears the aldehyde or ketone functional group in the compound's acyclic, open-chain configuration, known as the anomeric carbon.
=== January === 1 January Researchers operating China's Experimental Advanced Superconducting Tokamak (EAST) report the first experimental verification of a theorised density-free plasma operating regime, achieving stable electron densities approximately 1.3–1.65 times the Greenwald limit. Researchers at the Korea Advanced Institute of Science and Technology report a photo-Hall (Hall effect)–based method for detecting semiconductor electronic trap states with approximately 1,000-fold greater sensitivity than existing techniques. 2 January – Researchers at the Vienna University of Technology and the Okinawa Institute of Science and Technology demonstrate self-sustained superradiant microwave emission, produced by interacting spins in diamond, offering potential applications in quantum communication and sensing. 5 January – NASA announces that it has awarded contracts to seven companies to study technologies for the Habitable Worlds Observatory, a next-generation telescope that could launch in the 2040s. 7 January – Astronomers using data from the Vera C. Rubin Observatory report that 2025 MN45 has the fastest spin of any known asteroid larger than 0.5 km (0.31 mi) in diameter, completing one rotation every 1.88 minutes. 13 January The European Copernicus Climate Change Service reports that 2025 was the world's third hottest year on record (2024 was the hottest year and 2023 the second hottest). In Antarctica, the average annual temperature was the warmest since measurements began and in the Arctic, it was the second highest.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.